DAWNDay One Biopharmaceuticals, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$103,000

Operating Income

-$60M

Net Income

-$55M

EPS (Diluted)

$-0.62

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$376M

Total Liabilities

$30M

Stockholders' Equity

$347M

Cash & Equivalents

$231M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$103,000	-$180,000	+42.8%
Operating Income	-$60M	-$43M	-39.2%
Net Income	-$55M	-$40M	-35.9%

DAWN Q4 2023 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena